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Background: Two isoforms of Rho-associated protein kinase (ROCK), ROCKI and ROCKII, play a pivotal role in
regulation of cytoskeleton and are involved in multiple cellular processes in mammalian cells. Knockout mice
experiments have indicated that the functions of ROCKI and II are probably non-redundant in physiology. However,
it is difficult to differentiate the activation status of ROCKI and ROCKII in biological samples. Previously, we have
identified phosphorylation site of ROCKII at Ser1366 residue sensitive to ROCK inhibition. We further investigated
the activity-dependent phosphorylation site in ROCKI to establish the reagents that can be used to detect their
individual activation.
Results: The phosphorylation site of ROCKI sensitive to its inhibition was identified to be the Ser1333 residue.
The ROCKI pSer1333-specific antibody does not cross-react with phosphorylated ROCKII. The extent of S1333
phosphorylation of ROCKI correlates with myosin II light chain phosphorylation in cells in response to RhoA
stimulation.
Conclusions: Active ROCKI is phosphorylated at Ser1333 site. Antibodies that recognize phospho-Ser1333 of ROCKI
and phospho-S1366 residues of ROCKII offer a means to discriminate their individual active status in cells and
tissues.
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Two isoforms of Rho-associated protein kinase (ROCK),
ROCKI (also called ROKβ) and ROCKII (also known as
Rho kinase and ROKα) have been identified as RhoA-GTP
interacting proteins in mammals [1,2]. They are serine/
threonine kinases important for regulation of actin dy-
namics and cytoskeleton organization [3-5]. These two
human kinases share 64% homology in amino acid se-
quence with 89% identity in the catalytic kinase domain
[5]. They contain a Rho-binding domain (RBD) in the
coiled-coil region and a pleckstrin homology (PH)
domain in the C-terminal region, which folds back onto
the N-terminal kinase domain to autoinhibit kinase func-
tions. GTP-RhoA binding relieves the auto-inhibition,
switching-on the kinase activity [6]. ROCKI and ROCKII
have common substrates, such as myosin light chain* Correspondence: zfchang@ym.edu.tw; hhl@ym.edu.tw
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reproduction in any medium, provided the or(MLC), myosin binding subunit (MYPT1) of the MLC
phosphatase, LIM kinases (LIMK1 and LIMK2), α-
adducin, ezrin-radixin-moesin (ERM) proteins, and etc.
[4,5,7-9]. Collectively, the kinase activation promotes the
stabilization of actin filaments and myosin activity to in-
crease actomyosin-driven cellular contractility [10,11]. In
addition to regulation by RhoA binding, ROCKs are nega-
tively regulated by distinct binding proteins or phosphor-
ylation. For example, Gem and RhoE specifically inhibit
ROCKI and Rad for ROCKII inhibition [5,12]. ROCKII
has been shown to be phosphorylated at Tyr722 residue
by Src kinase to decrease its affinity to GTP-RhoA [13],
and dephosphorylated by Shp2 phosphatase [14]. There-
fore, the activity of ROCKI and II in vivo could be highly
dependent on the cellular context.
To know the distinct biological roles of ROCKI and
ROCKII, the ROCKI−/− and ROCKII−/− mice have been
generated [15,16]. ROCKI−/− mice are postnatal lethal,
because of impairment of umbilical ring closure [16],
and ROCKII−/− mice are embryonic lethal at the per-
centage of 90% due to the dysfunction of placenta andl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mation in the labyrinth layer of placenta [15]. These
studies suggest that ROCKI and ROCKII have distinct
functions in development.
Many reports have highlighted the association of ROCK
activation with cancer progression and suggest the poten-
tial of ROCK as therapeutic targets in cancer [17-19]. The
level of ROCKI RNA in tumor tissue correlates with the
tumor grade and poor overall survival in breast cancer pa-
tients [20], and higher level of ROCKI protein has been
found in osteosarcoma tissues [21]. As for ROCKII, higher
expression has been reported in aggressive hepatocellular
carcinomas, colon and bladder cancers [22-24]. Consider-
ing that the expression level at mRNA or protein of ROCK
may not be necessarily correlated with their kinase activ-
ity, we developed the reagents that can directly and specif-
ically detect the activation status of ROCKI and ROCKII
in cells and tissues by identification of their corresponding
phosphorylation sites. Our previous results have provided
evidence that ROCKII at Ser1366 residue reflects its kin-
ase activation [25]. In this study, we further showed acti-
vated ROCKI with phosphorylation at Ser1333 residue.
Thus, the specific antibodies, one against ROCKI Ser1333
phosphorylation and another against ROCKII Ser1366
phosphorylation, can be used to detect the active form of
ROCKI and ROCKII, respectively.
Methods
Plasmids and reagents
The S1333A mutation of ROCKI was introduced to wild-
type pCMV2-flag-ROCKI described previously [25] using
the Quick-Change site-directed mutagenesis kit (Strata-
gene). Y27632 was from Calbiochem-Novabiochem Corp.;
λPPase was from New England Biolabs; nocodazole, anti-
flag and anti-MLC antibodies were from Sigma-Aldrich;
anti-ROCKI, anti-ROCKII and anti-RhoA antibodies
were purchased from Santa Cruz Biotechnology; anti-
phospho-MLC2 (T18/S19) antibody from Cell Signaling
Technology; anti-pSer1366 ROCKII antibody was de-
scribed previously [25].
Cell culture and transient transfection
Normal mouse embryonic fibroblasts (MEFs) and
HEK293T cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (v/v)
fetal bovine serum (FBS) in a humidified atmosphere of
5% CO2/95% air at 37°C. For transient transfection ex-
periments, HEK293T cells were transfected by PolyJet
reagent (SignaGen Laboratories).
Immunoprecipitation and in vitro kinase reaction
Flag-ROCKI-expressing cells were harvested in an IP
buffer (1% NP-40, 5% glycerol, 50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1 mM PMSF, 50 mM NaF, 2 mMNa3VO4 and protease inhibitor cocktail). The lysates
after pre-clearance were incubated with anti-flag antibody
conjugated agarose beads (Sigma-Aldrich) at 4°C for 1 hr.
The immunoprecipitates were pre-incubated with or with-
out 100 μM of Y27632, which was followed by incubation
with a kinase buffer (50 mM Tris–HCl, pH7.4, 10 mM
MgCl2, 1 mM EGTA, 0.5 mM DTT, 5 mM NaF, 0.1 mM
Na3VO4, and 20 μM ATP) containing 5 μCi of [γ-
32p]ATP
at 30°C for 20 min. The reaction was stopped and
products were separated by SDS-PAGE, transferred to a
PVDF membrane. The phosphorylation status and amounts
of the proteins were detected by autoradiography and
Western blotting with anti-ROCKI antibody, respectively.
Phospho-specific antibody generation
The polyclonal anti-pS1333 ROCKI antibody was raised
using phosphopeptide containing phosphorylated
Ser1333 of ROCKI conjugated with keyhole limpet hae-
mocyanin (KLH) as an antigen to immunize rabbits.
Anti-sera were collected and sequentially affinity pu-
rified by phosphopeptide- and non-phosphopeptide-
conjugated columns (ICON Biotechnology Co., Itd.,
Taiwan).
Results and discussion
Identification of activity-dependent phosphorylation site
of ROCKI
To search for kinase-dependent phosphorylation site of
ROCKI, we performed an in vitro kinase reaction using
immunoprecipitated flag-tagged ROCKI protein in the
presence of [γ-32P]ATP. Autoradiography detected the
phosphorylation signal, which was abolished by including
ROCK inhibitor Y27632 in the in vitro kinase reaction
(Figure 1A). Ser1333 residue in human ROCKI sequence
is corresponding to the Ser1366 of ROCKII and is con-
served in vertebrates. We then isolated immunocomplex
of wild-type (WT) and S1333A mutant of flag-ROCKI
proteins in cells for the in vitro kinase assay using [γ-32P]
ATP labeling. The result showed that S1333A mutation
markedly reduced the intensity of [γ-32P]ATP labeling in
ROCKI (Figure 1B), indicating that Ser1333 residue is one
of the phosphorylation sites of ROCKI dependent on its
own kinase activity.
Validation of Ser1333 phosphorylation of ROCKI by
specific antibody
To assure that phosphorylation at Ser1333 is a mark of
ROCKI activation in biological samples, we then gener-
ated a phospho-specific antibody by a phosphopeptide
containing pSer1333 of ROCKI. The specificity of this
antibody was tested by Western blot analysis of the
immunoprecipitated WT and S1333A mutant of flag-
ROCKI proteins. The results showed that purified anti-
pS1333 ROCKI antibody was capable of detecting the
Figure 1 ROCKI is phosphorylated at Ser1333 residue. (A) The
flag-ROCKI protein was expressed in HEK293T cells and
immunoprecipitated with anti-flag antibody. Equal amounts of
immunoprecipitated complex were pre-incubated with 100 μM of
Y27632 for 20 min and subjected to an in vitro kinase reaction with
5 μCi of [γ-32P] ATP. (B)Wild-type (WT) and S1333A mutant of
flag-ROCKI proteins were immunoprecipitated for in vitro kinase
reaction. After 20 min, the reaction was stopped and proteins were
then applied to SDS-PAGE followed by autoradiography. The protein
level of flag-ROCKI was determined by Western blotting with
anti-ROCKI antibody.
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S1333A flag-ROCKI protein. The signal was neutralized
by phosphorylated peptide but not by non-phosphorylated
peptide (Figure 2A). Treatment of flag-ROCKI (WT) im-
munoprecipitates with λ protein phosphatase (λPPase)Figure 2 Validation of anti-pSer1333 ROCKI antibody. (A) Wild-type (W
HEK293T cells and immunoprecipitated with anti-flag antibody followed by
without peptide competition in a same set of sample. (B) WT flag-ROCKI im
20 min followed by Western blot analysis as indicated. (C) Flag-tagged ROC
analysis using anti-pSer1333 ROCKI, anti-pSer1366 ROCKII, and anti-flag antiabolished the signal (Figure 2B). These data indicate the
specificity of anti-pSer1333 ROCKI antibody. Given the
similarity in amino acid sequence surrounding Ser1333 in
ROCKI and Ser1366 in ROCKII, we used flag-tagged
ROCKI and ROCKII immunoprecipitates to verify the
specificity of these two antibodies. As shown in Figure 2C,
neither did anti-pSer1333 ROCKI antibody cross-react
with ROCKII, nor anti-pSer1366 ROCKII antibody to
ROCKI.Detection of endogenous ROCKI activation by assessing
Ser1333 phosphorylation
We further used this antibody for direct Western blot ana-
lysis of lysates from HEK293T cells expressing WT and
S1333A ROCKI. As shown in Figure 3A, the antibody de-
tected a major signal in WT ROCKI but not S1333A mu-
tant. A lower band was a non-specific signal because the
intensity was similar regardless of the ectopic expression
of ROCKI. Next, we assessed the change in Ser1333 phos-
phorylation of endogenous ROCKI in response to RhoA
activation. To this end, HEK293T cells were transfected
with the expression construct of GFP-RhoAV14, a consti-
tutively active form, GFP-RhoAN19, a dominant negative
form, or GFP-RhoAV14E40L, a constitutive active mutant
defective in interaction with ROCK [26], for Western blot
analysis. The level of Ser1333 phosphorylation of ROCKI
in cells was increased by expression of GFP-RhoAV14.
However, expression of GFP-RhoAV14E40L had no effect
on the level Ser1333 phosphorylation of ROCKI. Exp-
ression of GFP-RhoAN19 reduced ROCKI Ser1333
phosphorylation (Figure 3B). These data suggest that the
activation of endogenous ROCKI by RhoA can be specific-
ally detected by Western blot analysis using anti-pSer1333
ROCKI antibody.T) or S1333A mutant of flag-ROCKI proteins were expressed in
probed with anti-flag or anti-pSer1333 ROCKI antibody with or
munoprecipitates were incubated with or without λPPase at 30°C for
KI and ROCKII proteins were immunoprecipitated for Western blot
bodies in a same set of sample.
Figure 3 Detection of endogenous ROCKI phosphorylation at
Ser1333 residue. (A) HEK293T cells expressing WT or S1333A
mutant of flag-ROCKI were harvested for Western blot analysis with
anti-pS1333 ROCKI and anti-ROCKI antibodies. (B) Cells were
transfected with the expression constructs of GFP, GFP-RhoAV14,
GFP-RhoAV14E40L, or GFP-RhoAN19 and harvested for Western
blotting with antibodies as indicated. *, non-specific signal.
Chuang et al. Journal of Biomedical Science 2013, 20:83 Page 4 of 6
http://www.jbiomedsci.com/content/20/1/83We also examined the changes of ROCKI S1333 phos-
phorylation in serum-starved mouse embryonic fibroblasts
(MEFs) that were treated with nocodazole to activate the
RhoA signal via GEF-H1 released from microtubules disas-
sembly [27]. As shown in Figure 4, ROCKI Ser1333 phos-
phorylation level was dramatically increased (5-fold) by
nocodazole treatment at 15 min as seen in the increase of
MLC phosphorylation. Similarly, the phosphorylation of
ROCKII at Ser1366 was also increased. Treatment of cells
with Y27632 prevented both nocodazole-induced ROCKI
S1333 and ROCKII S1366 phosphorylation, suggesting the
increase of the phosphorylation signal correlates with their
corresponding kinase activation. The Y27632 treatment did
not completely abolish the basal levels of ROCKI S1333
phosphorylation and ROCKII S1366 phosphorylation. ItFigure 4 Probing ROCKI and ROCKII activation in cells. Normal
mouse embryonic fibroblasts (MEFs) were serum starved for 24 hr
and then stimulated with 10 μM of nocodazole in the presence or
absence of 10 μM of Y27632. Cells were harvested at the indicated
time for Western blotting with antibodies as indicated. The fold of
relative protein phosphorylation was measured and showed.is uncertain whether this is due to the incomplete inhib-
ition of ROCK kinase or a background level of non-
specific signal. Nevertheless, the stimulation effect is
reflected by these phosphorylation marks. Interestingly,
the level of ROCKII S1366 phosphorylation was de-
clined to the basal level at 60 min, while ROCKI S1333
phosphorylation sustained to 120 min. Thus, probing
ROCKI Ser1333 and ROCKII Ser1366 phosphorylation
is able to discriminate the differences in the kinetic of
ROCKI and ROCKII activation in cells.
It is known that ROCKs form dimer [28-32]. In this
study, we did not examine whether ROCKI S1333 phos-
phorylation is due to ROCKII in the heterodimer. It has
been reported that the dimer consisting of wild-type kinase
and catalytic-dead ROCK kinase domain is catalytically in-
active [30]. Therefore, we are unable to test whether
ROCKII can phosphorylate catalytic-dead ROCKI at S1333
in the heterodimer form. In an overexpression experiment,
we found that the amount of homodimer of ROCKII was
more than 10-fold higher than that of ROCKI/II (data not
shown). Considering that all ROCKs purified from a variety
of tissues have been shown to be in homodimer form
[2,33-35], the physiological significance of S1333 phosphor-
ylation in the heterodimer form of ROCKI/II is probably
negligible. We also cannot exclude the possibility that other
kinase is able to phosphorylate the S1333 site. Nevertheless,
the correlation of S1333 phosphorylation with its upstream
RhoA regulation and the extent of downstream substrate
MLC phosphorylation suggest this modification as an indi-
cator of ROCKI activation.
Small-molecule inhibitors against ROCK, such as Y27632
and Fasudil, have been developed to have potential in clin-
ical implication [17,36,37]. Increasing number of clinical tri-
als and animal experiments using these inhibitors suggest
that ROCK activation plays an important role in the patho-
genesis of many cardiovascular diseases, neurological disor-
ders and cancers [3,4,38-43]. Although the functions of
ROCKI and ROCKII are analogous and compensatory, gen-
etic deletion studies suggest that each kinase might play dis-
tinct roles depending on tissue types and certain biological
processes. Also unknown is which ROCK isoform is re-
sponsible for pathogenesis of a specific tissue in diseases
and related to disease progression. Our antibodies that can
detect the phosphorylation of ROCKI at Ser1333 and
ROCKII at Ser1366 offer new opportunities to differentiate
the activation status of ROCKI and II in association with
diseases. Of note, all the current inhibitors cannot discern
between ROCKI and II. The antibodies that can detect ac-
tive forms of ROCKI and II provide valuable tools for
screening ROCKI and ROCKII specific inhibitors.
Conclusion
Ser1333 phosphorylation can indicate the active status of
ROCKI in response to RhoA signaling. Thus, antibodies
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residues of ROCKI and II, respectively, are capable of
probing their corresponding activation in biological
samples. Also, these antibodies might be very useful re-
agents for drug screening of inhibitors specific against
ROCKI and ROCKII isoform.
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